Obstructive hydrocephalus, fifth nerve and hypothalamus involvement: Acute presentation of a giant prolactinoma

Clinical Medicine Insights: Case Reports

Volumn 5, Issue , 2012, Pages 115-118

  Alkatari, Shadin ^a   Aljohani, Naji ^b,c  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b KING FAHAD MEDICAL CITY   (Saudi Arabia)

^c KSAU HC   (Saudi Arabia)

Author keywords

(IGP) invasive giant prolactinoma; Obstructive hydrocephalus

Indexed keywords

CABERGOLINE; PROLACTIN;

ADULT; ARAB; ARTICLE; BRAIN HEMORRHAGE; BRAIN THIRD VENTRICLE; CASE REPORT; CAVERNOUS SINUS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE DURATION; DRUG DOSE INCREASE; HEADACHE; HUMAN; HYPOPHYSIS TUMOR; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSTRUCTIVE HYDROCEPHALUS; PARESTHESIA; PROLACTIN BLOOD LEVEL; PROLACTINOMA; SPHENOID SINUS; TREATMENT OUTCOME; TRIGEMINAL NERVE DISEASE; TUMOR LOCALIZATION; TUMOR VOLUME; VOMITING;

EID: 84865028783     PISSN: 11795476     EISSN: 11795476     Source Type: Journal    
DOI: 10.4137/CCRep.S9675     Document Type: Article

References (15)

1. Partington MD, Davis DH, Laws ER Jr, Scheithauer BW. Pituitary adenomas in childhood and adolescence. Results of transphenoidal surgery. J Neurosurg. 1994;80:209-16.
2. Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J. Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab. 1997;82:2102-7.
3. Kleiberg DL, Noel GL, Frantz AG. Galactorrhea. A study of 235 cases, including 48 with pituitary tumors. N Engl J Med. 1977;296:589-600.
4. Klibanski A, Neer RM, Bitins IZ, Ridgway EC, Zervas NT, McArthur JW. Decreased bone density in hyperprolactinemic women. N Engl J Med. 1980; 303:1511-4.
5. Hollenhorst RW, Younge BR. Ocular manifestations produced by adenomas of the pituitary gland: analysis of 1000 cases. In: Kohler PO, Ross GT, editors. Diagnosis and treatment of pituitary Tumors New York: Elsevier; 1973:53-64.
6. Zikel OM, Atikinson JL, Hurley DL. Prolactinoma manifesting with symptomatic hydrocephalus. Mayo Clin Proc. 1999;74:475-7.
7. Shrivastava RK, Arginteanu MS, King WA, Post KD. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg. 2002;97(2):299-306.
8. Muralidhara KS, Ahmed A, Darko D. Dramatic response with medical treatment of an extensively invasive 'giant' prolactinoma with cabergoline. Endocrine Abstracts. 2004;8:50.
9. Berwaerts J, Verhelst J, Abs R, Appel B, Mahler C. A giant prolactinoma presenting with unilateral exophthalmos. J Endocrinol Invest. 2000;23(6): 393-8.
10. Maccagnan P, Macedo CL, Kayath MJ, Nogueira RG, Abucham J. Conservative management of pituitary apoplexy: a prospective study. J Clin Endocrinol Metab. 1995;80:2190-7.
11. Shrivastava Raj K, Arginteanu Marc S, King Wesley A, Post Kalmon D. Giant prolactinomas: clinical management and long-term follow up. J Neurosurg. 2002;97(2):299-306.
12. Acharya SV, Gopal RA, Menon PS, Bandgar TR, Shah NS. Giant prolactinoma: Efficacy of medical management. Endocr Pract. 2009;24:1-14.
13. Corsello SM, Ubertini G, Altomare M, Lovicu RM, Migneco MG, Rota CA Colosimo. Giant prolactinomas in men: efficacy of cabergoline treatment. Clin Endocrinol. 2003;58(5):662-70.
14. Wu ZB, Yu CJ, Su ZP, Zhuge QC, Wu JS, Zheng WM. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg. 2006;104(1):54-61.
15. Shimon I, Benbassat C, Hadani M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur J Endocrinol. 2007; 156:225-31.